ART BioScience
Genetic Therapies for Duchenne Muscular Dystrophy
StartupART BioScience is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2015. Genetic Therapies for Duchenne Muscular Dystrophy. ART BioScience was founded by Oren Ozeri and Alon Hazan. The company has 1-10 employees. Core technologies: Biologicals, Genes, Molecules.
The company follows a B2B business model. Product stage: R&D.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQRehovot
- DistrictCenter District
- Last RoundUndisclosed
Oren Ozeri Co-founder, CEO & CTO
Alon HazanCo-founder
What does ART BioScience do?
ART BioScience specializes in the use of novel messenger RNA technologies for the development of therapeutics that may potentially change the course of Duchenne Muscular Dystrophy. The company’s initial work began with lipids licensed from the laboratory of Professor Dan Peer. ART BioScience has optimized these lipids for effective muscle delivery based on a proprietary LNP-based formulation. The delivery system enables the efficient transfer of mRNA to the muscles via systemic administration. The technology reflects years of work scanning numerous lipids and optimizing the formulations for delivery. ART BioScience was founded by Mr. Oren Ozeri and Mr. Alon Hazan, fathers of two children diagnosed with Duchenne Muscular Dystrophy.
Who founded ART BioScience?
ART BioScience was founded in 2015 by Oren Ozeri (Co-founder, CEO & CTO), Alon Hazan (Co-founder).
What sector is ART BioScience in?
ART BioScience operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is ART BioScience located?
ART BioScience is based in Prof. A. D. Bergman Street 2, Rehovot, Israel, Center District.